Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10298MR)

This product GTTS-WQ10298MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Heterozygous familial hypercholesterolemia (HeFH) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ10298MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2512MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 334
GTTS-WQ6912MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ENB-0040
GTTS-WQ8583MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ206MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 13C5.5
GTTS-WQ7070MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ1614MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACE-536
GTTS-WQ13205MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-04950615
GTTS-WQ2788MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG-282
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW